Anxiolytic-Like Effects of the Corticotropin-Releasing Factor1 (CRF1) Antagonist DMP904 [4-(3-pentylamino)-2,7-dimethyl-8-(2-methyl-4-methoxyphenyl)-pyrazolo-[1,5-a] -pyrimidine] Administered Acutely or Chronically at Doses Occupying Central CRF1 Receptors in Rats

Journal of Pharmacology and Experimental Therapeutics

Volumn 309, Issue 1, 2004, Pages 293-302

  Lelas, Snjezana ^a   Wong, Harvey ^a   Li, Yu Wen ^a   Heman, Karen L ^a   Ward, Kathryn A ^a   Zeller, Kim L ^a   Sieracki, Kristine K ^a   Polino, Joseph L ^a   Godonis, Helen E ^a   Ren, Shelly X ^a   Yan, Xiao Xin ^a   Arneric, Stephen P ^a   Robertson, David W ^a   Hartig, Paul R ^a   Grossman, Scott ^a   Trainor, George L ^a   Taub, Rebecca A ^a   Zaczek, Robert ^a   Gilligan, Paul J ^a   McElroy, John F ^a  

^a BRISTOL MYERS SQUIBB   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

4 (3 PENTYLAMINO) 2,7 DIMETHYL 8 (2 METHYL 4 METHOXYPHENYL)PYRAZOLO[1,5 A]PYRIMIDINE; ALPRAZOLAM; ANXIOLYTIC AGENT; BENZODIAZEPINE DERIVATIVE; CHLORDIAZEPOXIDE; CORTICOSTERONE; CORTICOTROPIN RELEASING FACTOR ANTAGONIST; CORTICOTROPIN RELEASING FACTOR RECEPTOR; CORTICOTROPIN RELEASING FACTOR RECEPTOR 1; DMP 904; UNCLASSIFIED DRUG;

ACUTE DRUG ADMINISTRATION; ANIMAL EXPERIMENT; ANXIETY DISORDER; ARTICLE; ATAXIA; CHRONIC DRUG ADMINISTRATION; CONTROLLED STUDY; CORTICOSTERONE BLOOD LEVEL; DRUG EFFICACY; DRUG RECEPTOR BINDING; DRUG TOLERANCE; HYPOTHALAMUS HYPOPHYSIS ADRENAL SYSTEM; IC 50; LOCOMOTION; MALE; MAZE TEST; NONHUMAN; PRIORITY JOURNAL; RAT; RECEPTOR AFFINITY; RECEPTOR OCCUPANCY; SEDATION; STRESS; TRANQUILIZING ACTIVITY; WITHDRAWAL REFLEX;

ANIMALS; ANTI-ANXIETY AGENTS; ANXIETY; CHLORDIAZEPOXIDE; CORTICOSTERONE; DISCRIMINATION LEARNING; MALE; MAZE LEARNING; MOTOR ACTIVITY; PYRAZOLES; PYRIMIDINES; RATS; RATS, SPRAGUE-DAWLEY; RECEPTORS, CORTICOTROPIN-RELEASING HORMONE; SUBSTANCE WITHDRAWAL SYNDROME;

EID: 12144285808     PISSN: 00223565     EISSN: None     Source Type: Journal    
DOI: 10.1124/jpet.103.058784     Document Type: Article

References (21)

1. Costa E and Guidotti A (1996) Benzodiazepines on trial: a research strategy for their rehabilitation. Trends Pharmacol Sci 17:192-200.
2. File SE (1984) Behavioural pharmacology of benzodiazepines. Prog Neuropsychopharmacol Biol Psychiatry 8:19-31.
3. Gilligan PJ, Baldauf C, Cocuzza A, Chidester D, Zaczek R, Fitzgerald LW, McElroy J, Smith MA, Shen HS, Saye JA, et al. (2000) The discovery of 4-(3-pentylamino)-2,7-dimethyl-8-(2-methyl-4-methoxyphenyl)-pyrazolo-[1,5-a] -pyrimidine: a corticotropin-releasing factor (hCRF1) antagonist. Bioorg Med Chem 8:181-189.
4. Griebel G, Perrault G, and Sanger DJ (1998) Characterization of the behavioral profile of the non-peptide CRF receptor antagonist CP-154,526 in anxiety models in rodents. Comparison with diazepam and buspirone. Psychopharmacology (Berl) 138:55-66.
5. 1 receptor antagonist. II. Characterization in rodent models of stress-related disorders. J Pharmacol Exp Ther 301:333-345.
6. Habib KE, Weld KP, Rice KC, Pushkas J, Champoux M, Listwak S, Webster EL, Atkinson AJ, Schulkin J, et al. (2000) Oral administration of a corticotropin-releasing hormone receptor antagonist significantly attenuates behavioral, neuroendocrine, and autonomic responses to stress in primates. Proc Natl Acad Sci USA 97:6079-6084.
7. He L, Gilligan PJ, Zaczek R, Fitzgerald LW, McElroy J, Shen HS, Saye JA, Kalin NH, Shelton S, Christ D, et al. (2000) 4-(1,3-Dimethoxyprop-2-ylamino)-2,7-dimethyl-8-(2,4-dichlorophenyl)pyrazolo[1, 5-a]-1,3,5-triazine: a potent, orally bioavailable CRF(1) receptor antagonist. J Med Chem 43:449-456.
8. Heinrichs SC, De Souza EB, Schulteis G, Lapsansky JL, and Grigoriadis DE (2002) Brain penetrance, receptor occupancy and antistress in vivo efficacy of a small molecule corticotropin releasing factor type I receptor selective antagonist. Neuropsychopharmacology 27:194-202.
9. Hikichi T, Akiyoshi J, Yamamoto Y, Tsutsumi T, Isogawa K, and Nagayama H (2000) Suppression of conditioned fear by administration of CRF receptor antagonist CP-154,526. Pharmacopsychiatry 33:189-193.
10. Kehne JH, Coverdale S, McCloskey TC, Hoffman DC, and Cassella JV (2000) Effects of CRF(1) receptor antagonist, CP 154,526, in the separation-induced vocalization anxiolytic test in rat pups. Neuropharmacology 39:1357-1367.
11. Kirk RE (1968) Experimental Design: Procedures for the Behavioral Sciences. Brooks-Cole, Belmont.
12. 1 antagonist DMP696 fails to function as a discriminative stimulus and does not substitute for chlordiazepoxide in rats. Psychopharmacology (Berl) 166:408-415.
13. 1 antagonist DMP696: correlation with plasma drug exposure and anxiolytic efficacy. J Pharmacol Exp Ther 305:86-96.
14. Lundkvist J, Chai Z, Teheranian R, Hasanvan H, Bartfai T, Jenck F, Widmer U, and Moreau JL (1996) A non peptidic corticotropin releasing factor receptor antagonist attenuates fever and exhibits anxiolytic-like activity. Eur J Pharmacol 309:195-200.
15. McElroy JF, Miller JM, and Meyer JS (1987) Comparison of the effects of chlordiazepoxide and CL 218,872 on serum corticosterone concentrations in rats. Psychopharmacology (Berl) 91:467-472.
16. McElroy JF, Ward KA, Zeller KL, Jones KW, Gilligan PJ, He L, and Lelas S (2002) The CRF(1) receptor antagonist DMP696 produces anxiolytic effects and inhibits the stress-induced hypothalamic-pituitary-adrenal axis activation without sedation or ataxia in rats. Psychopharmacology (Berl) 165:86-92.
17. Rosenberg HC, Tietz EI, and Chiu TH (1991) Differential tolerance to the antipentylenetotrazol activity of benzodiazepines in flurazepam-treated rats. Pharmacol Biochem Behav 39:711-716.
18. Soderpalm B, Eriksson E, and Engel JA (1989) Anticonflict and rotarod impairing effects of alprazolam and diazepam in rat after acute and subchronic administration. Prog Neuropsychopharmacol Biol Psychiatry 13:269-283.
19. 2 receptors in fear and anxiety. Neurosci Biobehav Rev 25:627-636.
20. 1) receptors. J Pharmacol Exp Ther 305:57-69.
21. Zobel AW, Nickel T, Kunzel HE, Ackl N, Sonntag A, Ising M, and Holsboer F (2000) Effects of the high-affinity corticotropin-releasing hormone receptor 1 antagonist R121919 in major depression: the first 20 patients treated. Psychiatry Res 34:171-181.